Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Common Equity (2022 - 2025)

Mereo BioPharma (MREO) has disclosed Common Equity for 4 consecutive years, with $40.9 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 32.89% to $40.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.9 million through Dec 2025, down 32.89% year-over-year, with the annual reading at $40.9 million for FY2025, 32.89% down from the prior year.
  • Common Equity for Q4 2025 was $40.9 million at Mereo BioPharma, down from $46.6 million in the prior quarter.
  • The five-year high for Common Equity was $78.6 million in Q2 2024, with the low at -$72.5 million in Q3 2024.
  • Average Common Equity over 4 years is $43.3 million, with a median of $50.5 million recorded in 2023.
  • The sharpest move saw Common Equity plummeted 232.59% in 2024, then soared 164.24% in 2025.
  • Over 4 years, Common Equity stood at $51.4 million in 2022, then dropped by 1.68% to $50.5 million in 2023, then increased by 20.64% to $61.0 million in 2024, then tumbled by 32.89% to $40.9 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $40.9 million, $46.6 million, and $54.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.